Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients by Shusheng Wu, Huiqin Luo, Wenju Chen, Xudong Liu, Huimin Li, Mengge Li, Lihong Ke, Jiayu Niu, Bing Hu, Huijun Xu, Gang Wang, Ying Yan, Lulu Cao, Xiaoxiu Hu, Chenghui Li, Yifu He

Get full text